Switch theme
Sign up to access all valuation multiples
NIOX Group PLC is a medical device company that develops a range of therapies for asthma, chronic obstructive pulmonary disease, and allergy. The company has a single operating segment: NIOX. The NIOX segment relates to the portfolio of products used to improve asthma diagnosis and management by measuring fractional exhaled nitric oxide (FeNO). Geographically, it derives a majority of its revenue from the Asia Pacific and also has a presence in the European Union, the United States, the United Kingdom, and the Rest of the world.
2006
91
LTM Revenue $61.0M
LTM EBITDA $20.0M
$377M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
NIOX Group has a last 12-month revenue (LTM) of $61.0M and a last 12-month EBITDA of $20.0M.
In the most recent fiscal year, NIOX Group achieved revenue of $57.4M and an EBITDA of $16.6M.
NIOX Group expects next 12-month revenue of XXX and NTM EBITDA of XXX
See NIOX Group valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $61.0M | XXX | $57.4M | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | $41.5M | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | 72% | XXX | XXX | XXX |
| EBITDA | $20.0M | XXX | $16.6M | XXX | XXX | XXX |
| EBITDA Margin | 33% | XXX | 29% | XXX | XXX | XXX |
| EBIT | $14.3M | XXX | $10.6M | XXX | XXX | XXX |
| EBIT Margin | 23% | XXX | 18% | XXX | XXX | XXX |
| Net Profit | $9.4M | XXX | $5.1M | XXX | XXX | XXX |
| Net Margin | 15% | XXX | 9% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 2, 2025, NIOX Group's stock price is GBP 1 (or $1).
NIOX Group has current market cap of GBP 284M (or $390M), and EV of GBP 274M (or $377M).
See NIOX Group trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $377M | $390M | XXX | XXX | XXX | XXX | $0.02 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 2, 2025, NIOX Group has market cap of $390M and EV of $377M.
NIOX Group's trades at 6.6x EV/Revenue multiple, and 22.7x EV/EBITDA.
Equity research analysts estimate NIOX Group's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
NIOX Group has a P/E ratio of 41.4x.
See valuation multiples for NIOX Group and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $390M | XXX | $390M | XXX | XXX | XXX |
| EV (current) | $377M | XXX | $377M | XXX | XXX | XXX |
| EV/Revenue | 6.2x | XXX | 6.6x | XXX | XXX | XXX |
| EV/EBITDA | 18.9x | XXX | 22.7x | XXX | XXX | XXX |
| EV/EBIT | 26.4x | XXX | 35.6x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | 41.4x | XXX | 76.7x | XXX | XXX | XXX |
| EV/FCF | 18.2x | XXX | 16.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialNIOX Group's last 12 month revenue growth is 12%
NIOX Group's revenue per employee in the last FY averaged $0.6M, while opex per employee averaged $0.3M for the same period.
NIOX Group's rule of 40 is 35% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
NIOX Group's rule of X is 62% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for NIOX Group and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 12% | XXX | 12% | XXX | XXX | XXX |
| EBITDA Margin | 33% | XXX | 29% | XXX | XXX | XXX |
| EBITDA Growth | 13% | XXX | 33% | XXX | XXX | XXX |
| Rule of 40 | 35% | XXX | 41% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 62% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.6M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 27% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 6% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 54% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
NIOX Group acquired XXX companies to date.
Last acquisition by NIOX Group was XXXXXXXX, XXXXX XXXXX XXXXXX . NIOX Group acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was NIOX Group founded? | NIOX Group was founded in 2006. |
| Where is NIOX Group headquartered? | NIOX Group is headquartered in United Kingdom of Great Britain and Northern Ireland. |
| How many employees does NIOX Group have? | As of today, NIOX Group has 91 employees. |
| Who is the CEO of NIOX Group? | NIOX Group's CEO is Mr. Jonathan Charles Emms. |
| Is NIOX Group publicy listed? | Yes, NIOX Group is a public company listed on LON. |
| What is the stock symbol of NIOX Group? | NIOX Group trades under NIOX ticker. |
| When did NIOX Group go public? | NIOX Group went public in 2014. |
| Who are competitors of NIOX Group? | Similar companies to NIOX Group include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of NIOX Group? | NIOX Group's current market cap is $390M |
| What is the current revenue of NIOX Group? | NIOX Group's last 12 months revenue is $61.0M. |
| What is the current revenue growth of NIOX Group? | NIOX Group revenue growth (NTM/LTM) is 12%. |
| What is the current EV/Revenue multiple of NIOX Group? | Current revenue multiple of NIOX Group is 6.2x. |
| Is NIOX Group profitable? | Yes, NIOX Group is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of NIOX Group? | NIOX Group's last 12 months EBITDA is $20.0M. |
| What is NIOX Group's EBITDA margin? | NIOX Group's last 12 months EBITDA margin is 33%. |
| What is the current EV/EBITDA multiple of NIOX Group? | Current EBITDA multiple of NIOX Group is 18.9x. |
| What is the current FCF of NIOX Group? | NIOX Group's last 12 months FCF is $20.7M. |
| What is NIOX Group's FCF margin? | NIOX Group's last 12 months FCF margin is 34%. |
| What is the current EV/FCF multiple of NIOX Group? | Current FCF multiple of NIOX Group is 18.2x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
